DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in ARAKODA is tafenoquine succinate. One supplier is listed for this compound. Additional details are available on the tafenoquine succinate profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 210607
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 100MG BASE|
|Approval Date:||Aug 8, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jul 20, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Regulatory Exclusivity Expiration:||Aug 8, 2021|
|Regulatory Exclusivity Use:||NEW PRODUCT|
|Patent:||⤷ Free Forever Trial||Patent Expiration:||Dec 2, 2035||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE|
Complete Access Available with Subscription